You are here

Aduhelm

So far, so not-so-good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study finds

So far, so not-so-good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study finds

Fierce Pharma

Alzheimer's disease

Flag link:

House committees kick off investigation into how Biogen's Aduhelm won approval

House committees kick off investigation into how Biogen's Aduhelm won approval

Endpoints

Alzheimer's disease

Flag link:

Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug

Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug

BioPharma Dive

Alzheimer's disease

Flag link:

FDA Head Calls for Inspector General Investigation of Aduhelm Approval

FDA Head Calls for Inspector General Investigation of Aduhelm Approval

BioSpace

Flag link:

FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment

FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment

BioPharma Dive

Alzheimer's disease

Flag link:

Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases

Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases

Stat

accelerated approvals

neurodegenerative disease

Flag link:

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

Stat

Flag link:

ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits

ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits

Endpoints

Alzheimer's disease

Flag link:

FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report

FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report

Endpoints

accelerated approvals

Alzheimer's disease

Flag link:

Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?

Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?

Stat

Alzheimer's disease

Flag link:

Biogen says it may adjust Aduhelm price if more patients take it than expected

Biogen says it may adjust Aduhelm price if more patients take it than expected

Beckers Hospital Review

Alzheimer's disease

Flag link:

Warren, Cassidy want hearing on new Alzheimer's drug coverage

Warren, Cassidy want hearing on new Alzheimer's drug coverage

The Hill

Alzheimer's disease

Elizabeth Warren

Flag link:

FDA documents show how controversial Alzheimer's drug decision was reached

FDA documents show how controversial Alzheimer's drug decision was reached

BioPharma Dive

Alzheimer's disease

Flag link:

Woodcock defends Biogen's new Alzheimer's drug, says it has more supportive data than many past accelerated approvals

Woodcock defends Biogen's new Alzheimer's drug, says it has more supportive data than many past accelerated approvals

Endpoints

Alzheimer's disease

Flag link:

'This is not a shotgun approach to dementia': Hospital execs share how they're rolling out Aduhelm

'This is not a shotgun approach to dementia': Hospital execs share how they're rolling out Aduhelm

Beckers Hospital Review

Alzheimer's disease

Flag link:

First patient receives controversial Biogen Alzheimer's drug

First patient receives controversial Biogen Alzheimer's drug

NASDAQ

Alzheimer's disease

Flag link:

Public Citizen demands removal of top FDA officials over Biogen Alzheimer's approval

Public Citizen demands removal of top FDA officials over Biogen Alzheimer's approval

Seeking Alpha

Alzheimer's disease

Flag link:

Despite controversy, Biogen's Aduhelm is already generating enthusiasm among doctors: survey

Despite controversy, Biogen's Aduhelm is already generating enthusiasm among doctors: survey

Fierce Pharma

Alzheimer's disease

Flag link:

These 3 Words From the FDA Ensure the Biogen Drama Is Far From Over

These 3 Words From the FDA Ensure the Biogen Drama Is Far From Over

Motley Fool

accelerated approvals

Alzheimer's disease

Flag link:

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Stat

Alzheimer's disease

Flag link:

Pages